Isolation of mesenchymal stem cells from bone marrow wastes of spinal fusion procedure (TLIF) for low back pain patients and preparation of bone dusts for transplantable autologous bone graft with a serum glue

BioScience Trends

Volumn 4, Issue 3, 2010, Pages 110-118

  Ichiyanagi, Tomoko ^a   Anabuki, Kouki ^b   Nishijima, Yoji ^b   Ono, Hirohisa ^b  

^a NATIONAL INSTITUTE OF GENETICS   (Japan)

^b Nishijima Hospital   (Japan)

Author keywords

Bone dusts; Mesenchymal stem cells; Serum glue; TLIF procedure; Xenogenous material free preparation

Indexed keywords

BIOLOGICAL MARKER; FIBRIN; TISSUE ADHESIVE;

ARTICLE; AUTOTRANSPLANTATION; BONE MARROW CELL; BONE PROSTHESIS; BONE TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; CELL SEPARATION; CHEMISTRY; CYTOLOGY; EVALUATION; FEMALE; HUMAN; IMMUNOPHENOTYPING; INSTRUMENTATION; LOW BACK PAIN; MALE; MESENCHYMAL STEM CELL; METABOLISM; METHODOLOGY; PHYSIOLOGY; SPINE FUSION;

BIOLOGICAL MARKERS; BONE MARROW CELLS; BONE SUBSTITUTES; BONE TRANSPLANTATION; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; FEMALE; FIBRIN; HUMANS; IMMUNOPHENOTYPING; LOW BACK PAIN; MALE; MESENCHYMAL STEM CELLS; SPINAL FUSION; TISSUE ADHESIVES; TRANSPLANTATION, AUTOLOGOUS;

EID: 77957045588     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Comprehensive Survey of Living Conditions. In: Japanese Ministry of Health (Labour and Welfare, eds.). 2004. (in Japanese)
2. Suka M, Yoshida K. Musculoskeletal pain in Japan: prevalence and interference with daily activities. Mod Rheumatol. 2005; 15:41-47.
3. Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am. 2006; 88 Suppl 2:21-24.
4. Deyo RA, Gray DT, Kreuter W, Mirza S, Martin BI. United States trends in lumbar fusion surgery for degenerative conditions. Spine (Phila Pa 1976). 2005; 30:1441-1445; discussion 1446-1447.
5. Martin BI, Deyo RA, Mirza SK, Turner JA, Comstock BA, Hollingworth W, Sullivan SD. Expenditures and health status among adults with back pain and neck problems. JAMA. 2008; 299:656-664.
6. Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009; 302:58-66.
7. Kai T, Shao-qing G, Geng-ting D. In vivo evaluation of bone marrow stromal-derived osteoblasts-porous calcium phosphate ceramic composites as bone graft substitute for lumbar intervertebral spinal fusion. Spine (Phila Pa 1976). 2003; 28:1653-1658.
8. Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials. 2003; 24:2339-2349.
9. Sandhu HS, Boden SD. Biologic enhancement of spinal fusion. Orthop Clin North Am. 1998; 29:621-631.
10. Hacker RJ. A randomized prospective study of an anterior cervical interbody fusion device with a minimum of 2 years of follow-up results. J Neurosurg. 2000; 93:222-226.
11. Silber JS, Anderson DG, Daffner SD, Brislin BT, Leland JM, Hilibrand AS, Vaccaro AR, Albert TJ. Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa 1976). 2003; 28:134-139.
12. Robertson PA, Wray AC. Natural history of posterior iliac crest bone graft donation for spinal surgery: a prospective analysis of morbidity. Spine (Phila Pa 1976). 2001; 26:1473-1476.
13. Sasso RC, LeHuec JC, Shaffrey C. Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. J Spinal Disord Tech. 2005; 18 Suppl:S77-S81.
14. Muschler GF, Matsukura Y, Nitto H, Boehm CA, Valdevit AD, Kambic HE, Davros WJ, Easley KA, Powell KA. Selective retention of bone marrow-derived cells to enhance spinal fusion. Clin Orthop Relat Res. 2005; 432:242-251.
15. St John TA, Vaccaro AR, Sah AP, Schaefer M, Berta SC, Albert T, Hilibrand A. Physical and monetary costs associated with autogenous bone graft harvesting. Am J Orthop (Belle Mead NJ). 2003; 32:18-23.
16. Hsu WK, Wang JC, Liu NQ, Krenek L, Zuk PA, Hedrick MH, Benhaim P, Lieberman JR. Stem cells from human fat as cellular delivery vehicles in an athymic rat posterolateral spine fusion model. J Bone Joint Surg Am. 2008; 90:1043-1052.
17. Urrutia J, Mery P, Martínez R, Pizarro F, Apablaza D, Mardones R. Cultured autologous bone marrow stem cells inhibit bony fusion in a rabbit model of posterolateral lumbar fusion with autologous bone graft. J Clin Neurosci. 2010; 17:481-485.
18. Nakajima T, Iizuka H, Tsutsumi S, Kayakabe M, Takagishi K. Evaluation of posterolateral spinal fusion using mesenchymal stem cells: differences with or without osteogenic differentiation. Spine (Phila Pa 1976). 2007; 32:2432-2436.
19. Cornell CN. Osteoconductive materials and their role as substitutes for autogenous bone grafts. Orthop Clin North Am. 1999; 30:591-598.
20. Subach BR, Haid RW, Rodts GE, Kaiser MG. Bone morphogenetic protein in spinal fusion: overview and clinical update. Neurosurg Focus. 2001; 10:E3.
21. Wozney JM. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976). 2002; 27:S2-S8.
22. Sakaguchi Y, Sekiya I, Yagishita K, Ichinose S, Shinomiya K, Muneta T. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood. 2004; 104:2728-2735.
23. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci U S A. 2001; 98:7841-7845.
24. Shahdadfar A, Frønsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells. 2005; 23:1357-1366.
25. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8:315-317.
26. Ho W, Tawil B, Dunn JC, Wu BM. The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure. Tissue Eng. 2006; 12:1587-1595.
27. Catelas I, Sese N, Wu BM, Dunn JC, Helgerson S, Tawil B. Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro. Tissue Eng. 2006; 12:2385-2396.
28. Ogston N, Harrison AJ, Cheung HF, Ashton BA, Hampson G. Dexamethasone and retinoic acid differentially regulate growth and differentiation in an immortalised human clonal bone marrow stromal cell line with osteoblastic characteristics. Steroids. 2002; 67:895-906.
29. Jørgensen NR, Henriksen Z, Sørensen OH, Civitelli R. Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrowderived primary osteoblasts. Steroids. 2004; 69:219-226.
30. Sammons J, Ahmed N, El-Sheemy M, Hassan HT. The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev. 2004; 13:273-280.
31. Carvallo L, Henríquez B, Paredes R, Olate J, Onate S, van Wijnen AJ, Lian JB, Stein GS, Stein JL, Montecino M. 1alpha,25-dihydroxy vitamin D3-enhanced expression of the osteocalcin gene involves increased promoter occupancy of basal transcription regulators and gradual recruitment of the 1alpha,25-dihydroxy vitamin D3 receptor-SRC-1 coactivator complex. J Cell Physiol. 2008; 214:740-749.
32. Dai Z, Li Y, Quarles LD, Song T, Pan W, Zhou H, Xiao Z. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. 2007; 14:806-814.
33. Cheng MZ, Rawlinson SC, Pitsillides AA, Zaman G, Mohan S, Baylink DJ, Lanyon LE. Human osteoblasts' proliferative responses to strain and 17beta-estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I. J Bone Miner Res. 2002; 17:593-602.
34. Tondreau T, Lagneaux L, Dejeneffe M, Delforge A, Massy M, Mortier C, Bron D. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy. 2004; 6:372-379.
35. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284:143-147.
36. Eriksen JR, Bech JI, Linnemann D, Rosenberg J. Laparoscopic intraperitoneal mesh fixation with fibrin sealant (Tisseel) vs. titanium tacks: a randomised controlled experimental study in pigs. Hernia. 2008; 12:483-491.
37. Spotnitz WD. Commercial fibrin sealants in surgical care. Am J Surg. 2001; 182:8S-14S.
38. Landesberg R, Burke A, Pinsky D, Katz R, Vo J, Eisig SB, Lu HH. Activation of platelet-rich plasma using thrombin receptor agonist peptide. J Oral Maxillofac Surg. 2005; 63:529-535.